<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215917</url>
  </required_header>
  <id_info>
    <org_study_id>lichtenberg1CTIL</org_study_id>
    <nct_id>NCT00215917</nct_id>
  </id_info>
  <brief_title>D-Serine Monotherapy for Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <brief_summary>
    <textblock>
      N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic&#xD;
      medication, has reduced negative, depressive, and cognitive symptomatology. We will be&#xD;
      investigating the effect of D-serine, (DSR), a selective and potent NMDAR agonist, as&#xD;
      monotherapy for treatment resistant schizophrenics.&#xD;
&#xD;
      40 subjects on stable doses of risperidone will be randomized under double-blind conditions&#xD;
      into a treatment group, which will receive D-serine 2100 mg, or a control group, which will&#xD;
      continue to receive risperidone. Treatment will continue for 14 weeks.&#xD;
&#xD;
      Symptoms and side effects will be rated biweekly with the CGI, PANSS, BPRS, SAS, AIMS, and&#xD;
      UKU. Before and after the trial subjects will undergo neuropsychological assessments.&#xD;
      Baseline and post-trial levels of amino acids relevant to glutamatergic neurotransmission&#xD;
      (glutamate, glutamine, aspartate, glycine, serine, alanine) will be assessed.&#xD;
&#xD;
      The primary outcome measures of the study will be the PANSS total scores and the positive and&#xD;
      negative symptom cluster scores.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine 2100 mg daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DSM-IV criteria for chronic schizophrenia&#xD;
&#xD;
          2. Treatment resistant&#xD;
&#xD;
          3. aged 18-70&#xD;
&#xD;
          4. Two months on stable risperidone dose&#xD;
&#xD;
          5. PANSS positive symptom cluster score &gt;20&#xD;
&#xD;
          6. PANSS negative symptom cluster score &gt;22&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Substance abuse&#xD;
&#xD;
          2. Concurrent DSM IV axis I disorder&#xD;
&#xD;
          3. Serious medical disorder&#xD;
&#xD;
          4. Concurrent drug therapy that can obscure the effect of risperidone or DSR.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pesach Lichtenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzog Hospital, and Hadassah Medical School--the Hebrew University of Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pesach Lichtenberg, M.D.</last_name>
    <phone>972-2-6221154</phone>
    <email>licht@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzog Hospital, Department of Psychiatry</name>
      <address>
        <city>Jerusalem</city>
        <zip>91351</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pesach Lichtenberg, M.D.</last_name>
      <phone>972-2-5316929</phone>
      <email>licht@cc.huji.ac.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>September 18, 2005</study_first_submitted>
  <study_first_submitted_qc>September 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 1, 2006</last_update_submitted>
  <last_update_submitted_qc>May 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2006</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>NMDA</keyword>
  <keyword>D-serine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

